Our products and technology are developed through collaboration. These valuable connections enable BioMosaics to continue providing cutting edge products and service in the oncology diagnostics market.
Jorge Filmus PhD; Senior scientist, Biological Sciences, Sunnybrook Research Institute
Professor Filmus received his M.Sc.in clinical biochemistry in 1979 and a PhD in Biological Chemistry from the University of Buenos Aires, Argentina. He is currently Senior Scientist, Biological Sciences, Odette Cancer Research Program, Sunnybrook Research Institute and Professor, Department of Medical Biophysics, University of Toronto. His discovery of the specific expression of Glypican-3 in Hepatocellular Carcinoma led to the development of BioMosaics clinical diagnostic products and his involvement in our research effort is instrumental in understanding the biology of Glypican-3.
Dr. Filmus' research activities focus on the diagnosis and treatment of liver cancer, and the role of glypicans in inherited disorders and cancer.
Mei-Sze Chua PhD; Senior Research Scientist, Stanford University
Mei-Sze is a Senior Research Scientist in the Department of Surgery at Stanford University, where she is interested in translating bioinformatics and genomics data into improved methods for the diagnosis and treatment of liver cancer. Mei-Sze received her Ph.D. from the School of Pharmacy, University of Nottingham, England, where she was actively engaged in drug development for oncology. In her current position, she has successfully led multi-disciplinary projects in biomarker detection, molecular imaging, experimental therapeutics, and drug repositioning for liver cancer. She also collaborates with twoXAR, a biopharmaceutical company that uses bioinformatics and predictive analytics to accelerate the time taken for drug discovery.
Experimental therapeutics, Cancer diagnostic and prognostic markers, Therapeutic targets for hepatocellular carcinoma, Novel strategies for imaging hepatocellular carcinoma, Cancer genomics, Functional and chemical genomics.
Samuel So MD; Lui Hac Minh Professor in the School of Medicine, Stanford University
Dr. So is the Director of the Asian Liver Center and Liver Cancer Program at Stanford University, Stanford California, and is also the leader of the well-known Jade Ribbon Campaign, a national hepatitis B awareness effort. Additionally, Dr. So is a professor in the Department of Surgery at the Stanford University School of Medicine. He graduated from the Univ. of Hong Kong, Faculty of Medicine in 1978 and had additional post-graduate and residency training at the University of Minnesota Medical School in Minneapolis. His Clinical Focus in General Surgery is in GI Oncology, particularly liver cancer. He is the Founder and Director, Multidisciplinary Liver Cancer Program, Stanford University Medical Center and the Founder and Director, Asian Liver Center, Stanford University.
Treatment of Chronic Hepatitis B, Growth factors and signaling in hepatocellular carcinoma, Diagnostic imaging in hepatocellular carcinoma, Therapy of liver cancer.
Serge Jothy MD; Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto
Dr. Serge Jothy received his medical degree from the University of Bordeaux, France. He then moved to McGill University in Montreal, where he received a PhD in experimental medicine. Subsequently, he trained in anatomic pathology at Queen's University before returning to McGill and the Royal Victoria Hospital, Montreal, in a staff position. In 1997, having reached the position of Full Professor in the Department of Pathology at McGill, Dr. Jothy was at Sunnybrook Health Sciences Centre as Head, Division of Anatomic Pathology until 2001. He joined the Department of Laboratory Medicine at St. Michael’s Hospital in 2002 where he was the Chief of the department until June 2014.
In addition to his leadership and clinical activities, Dr. Jothy is an active scientist in the area of cancer cell biology and has published over 120 peer-reviewed papers. His laboratory is investigating the mechanisms used by cancer cells to invade adjacent normal tissues and produce distant metastases. The investigations focus on how tumour cells become motile by modulating cell adhesion mechanisms. By extension, the studies are also directed at understanding how molecular alterations in critical components of the extracellular matrix contribute to the invasion of tumour cells, and how various compounds can block tumour invasion.